Key result
The AGT M235T and ACE I/D polymorphisms were not significantly associated with blood pressure response to atenolol, lisinopril, or nifedipine SR in patients with essential hypertension.
Why the study?
Do AGT M235T or ACE I/D polymorphisms predict blood pressure response to atenolol, lisinopril, or nifedipine in patients with untreated essential hypertension?
RCT (n=107)
crossover
Do AGT M235T or ACE I/D polymorphisms predict blood pressure response to atenolol, lisinopril, or nifedipine in patients with untreated essential hypertension?
Genetic polymorphisms in the renin-angiotensin system (AGT M235T and ACE I/D) do not predict blood pressure response to common antihypertensive drugs.
No takes yet. Share an insight, caveat, or question.
Genotyping for AGT M235T or ACE I/D variants is not warranted to guide therapy; challenges candidate-gene hypotheses for response to these agents.
Dudley et al. (1996) conducted an RCT in untreated essential hypertension (n=107). Atenolol, lisinopril, and nifedipine SR vs. Placebo was evaluated on Change in systolic and diastolic blood pressure associated with AGT M235T and ACE I/D genotypes. The AGT M235T and ACE I/D polymorphisms were not significantly associated with blood pressure response to atenolol, lisinopril, or nifedipine SR in patients with essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: